D3 Drug delivery to the vagina Flashcards

1
Q

describe the anatomy of the vagina

A
  • S-shaped fibromuscular tube
  • 6-10cm in length
  • connects the uterus (starting at the cervix) to the external environment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

how many layers does the vaginal wall consist of and what are they?

A

4 layers:

  • epithelial layer
  • lamina propria
  • muscular layer
  • tunica adventitia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what happens to the epithelial layer of the vaginal wall during the menstrual cycle?

A

its thickness changes by approximately 200-300 micrometers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

describe and explain an adaptation of the epithelial layer of the vaginal wall

A
  • surface is covered in rugae
  • these provide distensibility, support and an increased surface area
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

other than the thickness of the vaginal epithelium, what else changes during the menstrual cycle?

A

the quantity and composition of the vaginal fluid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

the vagina doesn’t possess a gland itself. where does its fluid arise from?

A
  • cervical secretion
  • transudation from the blood vessels
  • secretion from the endometrium and fallopian tubes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

compare vaginal fluid production of a woman of childbearing age to a postmenopausal woman

A
  • reproductive aged women produce vaginal fluid at a rate of 3-4 g/h
  • postmenopausal women’s discharge production is reduced by 50%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what may the human vaginal fluid contain?

A

enzymes
enzyme inhibitors
proteins
carbohydrates
amino acids
alcohols
aromatic compounds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what can alter drug release patterns from a vaginal drug delivery system and how?

A
  • sexual activity
  • the volume and composition of vaginal fluid will be affected which affects drug release pattern
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how is the acidic pH of 3.8-4.2 maintained in the vagina?

A

lactic acid is produced from glycogen from the epithelial cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what happens to the pH of the vagina during menstruation?

A

it increases / becomes more alkaline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

other than menstruation, what may cause an increase in vaginal pH?

A
  • frequent acts of coitus (sexual intercourse)
  • presence of infection
  • being postmenopausal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

why may vaginal drug delivery be used for local drug action?

A
  • treatments for infections, dryness and irritation
  • contraception
  • induction of labour
  • abortion
  • vaginal administration also allows the use of smaller doses with reduced systemic delivery and toxicity (eg. miconazole for the treatment of vaginal infections)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

why may vaginal drug delivery be used for systemic drug action?

A
  • dense network of blood vessels
  • for patients where oral administration is restricted (eg. severe vomiting)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

why is the dense network of blood vessels in the vagina good for systemic drug delivery via the vagina?

A
  • vaginal vein form venous plexuses along the side of the vagina and blood from the vaginal vein moves into the inferior vena cava, avoiding the hepatic portal system
  • this means drugs delivered via the intravaginal route may exhibit higher bioavailability compared with the oral route since first-pass metabolism is avoided
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what does the vaginal drug delivery route have the potential for?

A
  • preferential delivery to the uterus
  • this is known as the ‘first uterine pass effect’
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

challenges of vaginal drug delivery

A
  • gender specificity
  • local irritation must be kept in mind
  • cultural sensitivity
  • influence of sexual intercourse (and many other factors)
  • variability in epithelium thickness, fluid volume and pH can make absorption unpredictable
  • leakage of the dosage form is inherent
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

describe how drugs may be absorbed in systemic delivery via the vagina. detail higher molecular weight drugs and what is avoided

A
  • similar to other mucosal routes of delivery, drugs may be absorbed transcellularly, paracellularly or via receptor-mediated routes
  • good vascularisation provides the potential for maintaining a concentration gradient for passive diffusion
  • avoids first pass metabolism
  • higher molecular weight drugs absorbed well compared to other mucosae
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what physiological challenges are there that affect absorption of drugs in the vagina?

A
  • cyclic changes in fluid volume may have either a negative or positive effect on drug absorption
  • cyclic changes in pH and changes in pH due to disease state or menopausal status may change the degree of ionisation and alter absorption characteristics of weak electrolyte drugs
  • changes in the vaginal epithelium thickness impact absorption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

cyclic changes in vaginal fluid volume may have either a negative or positive effect on drug absorption. explain this

A
  • for drugs that display poor water solubility, increases in fluid volume may result in greater absorption (greater volume for API to dissolve in and can only be absorbed if dissolved)
  • on the other hand, increased fluid may remove the drug from the vaginal cavity and limit absorption
  • overly viscous cervical mucus may present an extra barrier
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

changes in the vaginal epithelium thickness impact absorption. give an example of a drug group that is affected by this

A

the vaginal absorption of steroids is decreased by increased thickness of the vaginal epithelium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

describe secretion during the menstrual cycle

A
  • mucus secretion varies throughout the menstrual cycle
  • in the cervix, secretion is considerably increased by oestrogen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

why is secretion increased by oestrogen in the cervix?

A

to produce a favourable medium for spermatozoa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

describe the vaginal secretions during the luteal phase

A

fluid thin and less acidic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

describe the vaginal secretions during ovulation

A

jelly-like (egg white resemblance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

describe the pH and epithelium thickness at ovulation

A
  • pH is lowest
  • epithelium is thickest
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

other than increased secretion, what else does oestrogen cause in the menstrual cycle?

A
  • cornification of cells
  • enlargement of nuclei
  • increased deposits of glycogen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what 3 general factors can influence drug dissolution and membrane transport and, therefore, influence drugs’ absorption profiles?

A
  • menstrual cycle
  • pregnancy
  • age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

explain how pregnancy is a factor that can affect drug absorption in the vagina

A
  • the vaginal mucosa becomes thicker during this time
  • increased desquamation of the superficial vaginal mucosal cells with increased vaginal discharge can present an extra barrier
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

explain how age is a factor that can affect drug absorption in the vagina, in particular, pre-puberty

A
  • mucosal epithelium is thin
  • vaginal pH is higher (around 5)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

explain how age is a factor that can affect drug absorption in the vagina, in particular, post-menopause or after hysterectomy

A

oestrogen levels drop which means:
- epidermis is much thinner (4 cell layers)
- reduced elasticity and vascularisation
- reduced secretions
- reduced glycogen (used by lactobacillus) - pH can return to pH 7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

what are the consequences of the drop in oestrogen in postmenopausal women or women that have had a hysterectomy?

A
  • patients are more prone to dryness, irritation and infection
  • even if they’re not sexually active, patients may need lubrication
33
Q

indications for vaginal therapy

A
  • infections and STDs
  • induction of labour and abortion
  • spermicide
  • prevention of STD transmission
  • vaginal dryness in postmenopausal women
  • contraceptives
34
Q

what things may be used to treat infections and STDs via vaginal therapy?

A

antifungals
antibacterials
antiseptics
acidifying agents

35
Q

what may be used in vaginal therapy to induce labour or abortion?

A

prostaglandins
oxytocins

36
Q

intended use of a bioadhesive vaginal gel containing the therapeutic drug: progesterone

A
  • infertility
37
Q

intended use of a gel containing the therapeutic drug: metronidazole

A
  • bacterial infection
38
Q

intended use of a pessary containing the therapeutic drug: dinoprostone

A

induction of labour

39
Q

intended use of a veginal ring containing the therapeutic drug: etonogestrel and ethinyl estradiol

A

contraception

40
Q

intended use of a vaginal ring containing the therapeutic drug: estradiol

A

hormone therapy

41
Q

intended use of an ointment containing the therapeutic drug: tioconazole

A

anti fungal, vaginal candida infection

42
Q

intended use of a vaginal cream containing the therapeutic drug: clotrimazole

A

antifungal

43
Q

intended use of a tablet containing the therapeutic drug: estradiol

A

atrophic vaginitis

44
Q

what considerations in formulation design are there for vaginal drug delivery?

A
  • non-irritating, non-drying
  • must not burn or itch
  • easy to insert / apply
  • should not cause leaking
  • should not stain or discolour undergarments
  • formulation should not adversely affect sexual activity
  • should be discreet enough to be used without knowledge of male partner
  • should be compatible with vaginal environment
45
Q

why should vaginal drug delivery systems by compatible with the vaginal environment?

A
  • changing pH or microflora gives opportunities for pathogens to grow
46
Q

describe NuvaRing

A
  • vaginal ring containing drug entrapped in a polymer network
  • contains etonogestrel and ethinyl estradiol
47
Q

state examples of polymers that can be used in vaginal rings and why?

A
  • polysiloxanes
  • ethylene vinyl acetate copolymers
  • both of these are flexible, inert and non-irritating
48
Q

why do vaginal rings lower the incidence of side effects compared to contraceptive methods with daily intake? what does this help with?

A
  • avoids fluctuations in drug concentration
  • lowering the incidence of side effects will increase the acceptability of a product and thus enhance patient compliance
49
Q

what is ‘Replens’?

A
  • bioadhesive gel based on polycarbophil (an insoluble but water-swellable polymer)
50
Q

what does ‘Replens’ do?

A
  • binds and rehydrates vaginal epithelium via release of purified water to underlying cells
  • forms moist film over vaginal tissue, which remains attached to epithelial cell surfaces
  • treats vaginal dryness by lubricating vaginal wall
  • increases blood flow and restores acidic pH
51
Q

what can vaginal dryness be caused by?

A

menopause
breastfeeding
cancer treatment
diabetes

and other factors

52
Q

what does the rehydration of the vaginal epithelium mean for those suffering with vaginal dryness?

A

reduces incidence of vaginal itching, irritation and dyspareunia (genital pain before, during or after sex)

53
Q

can Replens be used by breast cancer patients? why / why not?

A
  • yes
  • it is non-hormonal so can be used
54
Q

how long does Replens gel last?

55
Q

insoluble particles larger than 50 micrometers are likely to cause what in a vaginal formulation?

A

mechanical irritation after administration

56
Q

if a fatty base is used in a vaginal formulation, what will happen to lipophilic and hydrophilic drugs?

A
  • lipophilic drug will solubilise in fatty bases
  • hydrophilic drug will be suspended
57
Q

explain what the solubility of a drug in the vehicle and body fluids impacts in a vagina formulation

A
  • solubility of drug in the vehicle and body fluids affects release of the drug from the formulation
  • drug tends to reside in the medium which it is more soluble in
58
Q

other than the solubility of the drug, what else affects the release of drug from a vaginal formulation?

A

the miscibility of the base with the bodily fluids

59
Q

what kind of base is preferred for the release of a drug that is highly lipophilic and not hydrophilic?

A

a water-soluble base is preferred for release

60
Q

what kind of base is preferred for the release of a drug that is highly hydrophilic and not lipophilic?

A

a lipid base is preferred for release of hydrophilic drugs

61
Q

what is a desirable combination for drug release when it comes to vaginal formulations?

A
  • a water-soluble form of a drug dispersed in a lipid base
  • this will ensure rapid release of drug and miscibility with vaginal fluids
62
Q

what vaginal formulation is difficult to optimise with regards to dose?

A
  • fatty pessaries when they contain greater than 10% oily drugs
  • hard to maintain the required mechanical strength and melting point (they become very soft)
63
Q

what are pessaries? how can they be prepared? what do they contain?

A
  • solid, single-dose preparations for vaginal insertion
  • can be prepared in various shapes, usually ovoid, with a volume and consistency suitable for insertion into the vagina
  • contain one or more active substances dissolved or dispersed in a suitable base that may be soluble or dispersible in water or may melt at body temperature releasing the drug
64
Q

what should the base be in pessaries?

A
  • non-irritating
  • physically and chemically stable
  • pharmacologically inert
65
Q

when is leakage less likely to be a problem with pessaries?

A

if the viscosity of the vehicle after melting or dispersing is high

66
Q

describe what happens when drugs from pessaries enter the systemic circulation, when is this an advantage?

A
  • enter without passing through the liver
  • advantage if the drug is inactivated by the liver
67
Q

common bases for pessaries

A
  • hydrophobic waxes, fats, witepsols
  • hydrophilic waxes, Macrogols, PEG
  • gelatin (hydrophilic), glycerogelatin
68
Q

what does the choice of pessary base depend on?

A

drug properties - there is no single ideal suppository base

69
Q

why is PEG (polyethylene glycol) a versatile pessary base?

A

various melting points can be achieved by varying the molecular weight:

  • low molecular weight (PEG 300 and PEG 600) = liquid at room temperature
  • medium molecular weight (1000 Da) = semi-solid
  • high molecular weight (>3000 Da) = waxy solid
70
Q

describe hydrophilic pessary bases

A

water miscible
mix well with secretions

71
Q

what characteristics should a pessary base have compared to the drug?

A

base with opposite characteristics to drug should be used so they partition our easily:

  • hydrophilic bases release hydrophobic drugs
  • hydrophobic bases release ionised drugs
72
Q

list some disadvantages of aqueous vehicles in pessaries

A
  • hygroscopic (attracts water leading to a painful sensation)
  • there are many incompatible drugs with aqueous vehicles
  • drug release may be slow because drugs tend to stay in base
  • a water-soluble drug analogue in a hydrophobic base is preferable
73
Q

what can drugs do to bases in pessaries?

A
  • may reduce melting point and viscosity
  • certain drugs can lower the melting point of the base making it necessary to re-optimise the formulation to achieve the melting point close to body temperature
74
Q

describe the use of surfactants in pessaries

A
  • aid spreading
  • may irritate the epithelium
  • can create an emulsion system which reduces drug release
75
Q

describe the use of gelatin in pessaries

A
  • can be a positive or negatively charged molecule depending on pH and gelatin type
  • can pose difficulties and must be considered
76
Q

what is possible if oppositely charged drugs are present in pessaries?

A

ionic binding of the oppositely charged drugs

77
Q

state 3 things that lower vaginal pH (make it more acidic)

A
  • high oestrogen levels
  • increased glycogen
  • lactobacilli presence
78
Q

list 7 things that increase vaginal pH (make it more alkaline)

A
  • menstruation
  • frequent acts of coitus (sex)
  • the presence of infection
  • age (postmenopausal)
  • reduced glycogen
  • low oestrogen levels
  • hysterectomy